Assessment of Genotoxic potential of Annonacin and Annona muricata L. extracts on human breast cancer (MCF-7) cells

Naik, Aditi Venkatesh; Krishnan, S.

doi:10.1007/s13596-020-00517-8

Cited by 12 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some acetogenins, such as annonacin are also coupled with toxicity due to the impedances with mitochondrial performance and reduction in energy production in cells suggestive of anti-proliferative potential [7,11]. While most studies performed for dose escalation to establish the efficacy of fractions in a range of diseases do not demonstrate relevant toxicity to animal models or humans, they are symptomatic that it may be safe for humans [8,[38][39][40][41][42]. Unlike most chemotherapy, our findings suggest the efficacy of LEAM with the dose mentioned has petite side effects to host indicating as potentially useful pharmaceutical material to manage cancer.…”

Section: Discussionmentioning

confidence: 99%

Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton’s Lymphoma Ascites mediated tumours in Swiss albino mice

Naik

Dessai

Krishnan

2020

Libyan Journal of Medicine

Self Cite

View full text Add to dashboard Cite

The use of plants as a source of sedative or treatment for cancer is reasonably widespread worldwide. Annona muricata Linn exhibits a vast array of medicinal and ethno-pharmaceutical benefits, attributed by different plant parts. The activity of this plant is regarded to the bio-production of secondary metabolites like alkaloids, phenols, flavonoids, and most unique group of compounds, namely, annonaceous acetogenins. Whilst this plant is gaining popularity as an anticancer treating plant, this study was undertaken to verify the plausible anticancer effect of leaf methanol extracts of A. muricata (LEAM). Acute toxicity study was carried to obtain safe dose in mice models using haematological, biochemical, and histological evaluations in Swiss albino mice. In-vitro cytotoxicity towards Dalton's Lymphoma Ascites (DLA) and Ehrlich Ascites Carcinoma (EAC) cell lines were determined by trypan blue exclusion method. In-vivo antitumour activity of LEAM (100, 200, and 500mg/kg b.wt.) was evaluated using DLA induced solid carcinoma and EAC induced ascites carcinoma models and its comparison with standard drug Cisplatin. Acute toxicity studies did not exhibit significant variations in treated mice suggesting diminutive side effects of LEAM. Statistical analysis revealed the IC 50 values for DLA and EAC cell lines as 85.56 ± 5.28 and 68.07 ± 7.39 µg/mL, respectively, indicating better cytotoxic activity against EAC than DLA cells. LEAM decreased the tumour burden in dose-dependent manner. In comparison, with different concentrations tested, treatment with LEAM (200 mg/kg b.wt. and 500 mg/kg b.wt.) significantly reduced the solid tumour volume development by 58.11% and 65.70%, respectively. While lifespan was prolonged up to 51.43% in 500 mg/kg b.wt. LEAM treated ascites tumour-induced mice. This study thus indicates that LEAM possesses potent cytotoxic and antineoplastic activity and calls for more methodical safety assessments and other end-points of anti-tumourigenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton’s Lymphoma Ascites mediated tumours in Swiss albino mice

Naik

Dessai

Krishnan

2020

Libyan Journal of Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, deregulated expression of CCN proteins is frequently involved in tumorigenesis and cancer progression. While the expression of CCN proteins varies in different cancer types, CCN1, CCN2, CCN3 and CCN4 participate in tumor development and act as oncogenes, but CCN1, CCN3, CCN5, and CCN6 inhibit tumor growth and play tumor-suppressive roles in breast carcinomas [ 2 , 11 , 12 ]. It can be said that CCN1 and CCN3 play a dual role in breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…In 2020 alone, almost 2.3 million women were diagnosed with breast cancer worldwide. Breast cancer is the most frequently reported cancer and the leading cause of cancer-related mortality in women globally [ 1 , 2 ]. Members of the CCN family are matricellular proteins that are present in the extracellular matrix (ECM).…”

Section: Introductionmentioning

confidence: 99%

Potential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives

et al. 2021

View full text Add to dashboard Cite

CCNs are a specific type of matricellular protein, which are essential signaling molecules, and play multiple roles in multicellular eukaryotes. This family of proteins consists of six separate members, which exist only in vertebrates. The architecture of CCN proteins is multi-modular comprising four distinct modules. CCN Proteins achieve their primary functional activities by binding with several integrin7 receptors. The CCN family has been linked to cell adhesion, chemotaxis and migration, mitogenesis, cell survival, angiogenesis, differentiation, tumorigenesis, chondrogenesis, and wound healing, among other biological interactions. Breast cancer is the most commonly diagnosed cancer worldwide and CCN regulated breast cancer stands at the top. A favorable or unfavorable association between various CCNs has been reported in patients with breast carcinomas. The pro-tumorigenic CCN1, CCN2, CCN3, and CCN4 may lead to human breast cancer, although the anti-tumorigenic actions of CCN5 and CCN6 are also present. Several studies have been conducted on CCN proteins and cancer in recent years. CCN1 and CCN3 have been shown to exhibit a dual nature of tumor inhibition and tumor suppression to some extent in quiet recent time. Pharmacological advances in treating breast cancer by targeting CCN proteins are also reported. In our study, we intend to provide an overview of these research works while keeping breast cancer in focus. This information may facilitate early diagnosis, early prognosis and the development of new therapeutic strategies.

show abstract

“…This natural phytochemical can exhibit a wide range of important therapeutic activities, including antioxidant [53], anti-inflammatory [54], antibacterial [55], antiviral [56], antidiabetic [57], and anticancer activities [58]. GNT has proven its ability against various types of human cancers such as lung [59], liver [60], prostate [61], pancreatic [62], skin [63], cervical [64], uterine [65], colon [66], kidney [67], bladder [68], neuroblastoma [69], gastric [70], esophageal [71], pituitary [72], salivary gland [73], testicular [74], ovarian [75], and finally, breast cancer [29].…”

Section: An Overview Of Genisteinmentioning

confidence: 99%

“…Several studies suggested that GNT exerts pleiotropic effects, including inhibiting the cell cycle [22], inducing the cellular apoptosis process [23,24], suppressing metastasis [25] and angiogenesis [26], modulating oxidative stress [27], and mammosphere formation [28] in in vitro BC models. Furthermore, this phytoestrogen exerts several synergistic activities, as it can enhance the efficacy of conventional drugs against BC and reduce chemotherapeutic drug resistance [29]. Moreover, many in vivo [30] and clinical trials [31] also support that GNT can be considered a promising chemopreventive agent for treating different types of BC.…”

Section: Introductionmentioning

confidence: 99%

Genistein, a Potential Phytochemical against Breast Cancer Treatment-Insight into the Molecular Mechanisms

Sohel

Biswas²,

Amin

et al. 2022

Processes

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common malignancies in women. Although widespread successful synthetic drugs are available, natural compounds can also be considered as significant anticancer agents for treating BC. Some natural compounds have similar effects as synthetic drugs with fewer side effects on normal cells. Therefore, we aimed to unravel and analyze several molecular mechanisms of genistein (GNT) against BC. GNT is a type of dietary phytoestrogen included in the flavonoid group with a similar structure to estrogen that might provide a strong alternative and complementary medicine to existing chemotherapeutic drugs. Previous research reported that GNT could target the estrogen receptor (ER) human epidermal growth factor receptor-2 (HER2) and several signaling molecules against multiple BC cell lines and sensitize cancer cell lines to this compound when used at an optimal inhibitory concentration. More specifically, GNT mediates the anticancer mechanism through apoptosis induction, arresting the cell cycle, inhibiting angiogenesis and metastasis, mammosphere formation, and targeting and suppressing tumor growth factors. Furthermore, it acts via upregulating tumor suppressor genes and downregulating oncogenes in vitro and animal model studies. In addition, this phytochemical synergistically reverses the resistance mechanism of standard chemotherapeutic drugs, increasing their efficacy against BC. Overall, in this review, we discuss several molecular interactions of GNT with numerous cellular targets in the BC model and show its anticancer activities alone and synergistically. We conclude that GNT can have favorable therapeutic advantages when standard drugs are not available in the pharma markets.

show abstract

Assessment of Genotoxic potential of Annonacin and Annona muricata L. extracts on human breast cancer (MCF-7) cells

Cited by 12 publications

References 49 publications

Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton’s Lymphoma Ascites mediated tumours in Swiss albino mice

Antitumour activity of Annona muricata L. leaf methanol extracts against Ehrlich Ascites Carcinoma and Dalton’s Lymphoma Ascites mediated tumours in Swiss albino mice

Potential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives

Genistein, a Potential Phytochemical against Breast Cancer Treatment-Insight into the Molecular Mechanisms

Contact Info

Product

Resources

About